Matt J. Duffy, Ph.D.
Affiliations: | 2010 | Georgia State University, Atlanta, GA, United States |
Area:
Journalism, Mass Communications, GeneralGoogle:
"Matt Duffy"Parents
Sign in to add mentor| Gregory C. Lisby | grad student | 2010 | Georgia State | |
| (Unnamed sources: A longitudinal review of the practice and its merits.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| AlSultan D, Kavanagh E, O'Grady S, et al. (2020) The novel low molecular weight MYC antagonist MYCMI-6 inhibits proliferation and induces apoptosis in breast cancer cells. Investigational New Drugs |
| Duffy MJ, McDermott EW, Crown J. (2018) Blood-based biomarkers in breast cancer: From proteins to circulating tumor cells to circulating tumor DNA. Tumour Biology : the Journal of the International Society For Oncodevelopmental Biology and Medicine. 40: 1010428318776169 |
| Duffy MJ, Synnott NC, Crown J. (2018) Mutant p53 in breast cancer: potential as a therapeutic target and biomarker. Breast Cancer Research and Treatment |
| Duffy MJ, Harbeck N, Nap M, et al. (2017) Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM). European Journal of Cancer (Oxford, England : 1990). 75: 284-298 |
| Duffy MJ, O'Donovan N, McDermott E, et al. (2016) Validated biomarkers: The key to precision treatment in patients with breast cancer. Breast (Edinburgh, Scotland) |
| Duffy MJ, Walsh S, McDermott EW, et al. (2015) Biomarkers in Breast Cancer: Where Are We and Where Are We Going? Advances in Clinical Chemistry. 71: 1-23 |
| Caiazza F, McGowan PM, Mullooly M, et al. (2015) Targeting ADAM-17 with an inhibitory monoclonal antibody has antitumour effects in triple-negative breast cancer cells. British Journal of Cancer. 112: 1895-903 |
| Synnott NC, McGowan PM, Pierce A, et al. (2015) PRIMA-1MET (APR-246): A novel targeted therapy for triple negative breast cancer? Journal of Clinical Oncology. 33: e12072-e12072 |
| Mullooly M, Conklin D, McGowan PM, et al. (2015) Neratinib to inhibit the growth of triple-negative breast cancer cells. Journal of Clinical Oncology. 33: 1099-1099 |
| Caiazza F, Murray A, Madden SF, et al. (2015) Enzalutamide: A new hormonal treatment for triple-negative breast cancer? Journal of Clinical Oncology. 33: 1071-1071 |